Eiger BioPharmaceuticals2018-03-13T10:47:27+00:00

IN THE NEWS

Eiger BioPharmaceuticals Prices Previously Announced Public Offering of Common Stock

October 23rd, 2018|

Eiger BioPharmaceuticals Prices Previously Announced Public Offering of Common Stock PALO ALTO, Calif., October 23, 2018 – Eiger BioPharmaceuticals, Inc. (NASDAQ: EIGR), a clinical-stage biopharmaceutical company focused on the accelerated development and commercialization of targeted therapies for rare and ultra-rare diseases, announced today the pricing of its previously announced underwritten public offering.  The Company announced that it is selling 4,200,798 shares of its common stock in the public offering at an offering price of $10.35 per share.  In connection with [...]

Eiger BioPharmaceuticals Receives FDA Rare Pediatric Disease (RPD) Designation for Lonafarnib for the Treatment of Progeria and Progeroid Laminopathies and Plans NDA Filing in 2019

October 22nd, 2018|

Eiger BioPharmaceuticals Receives FDA Rare Pediatric Disease (RPD) Designation for Lonafarnib for the Treatment of Progeria and Progeroid Laminopathies and Plans NDA Filing in 2019 - Designation Enables Priority Review Voucher Eligibility Upon NDA Approval PALO ALTO, Calif., October 22, 2018 — Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease (RPD) designation to lonafarnib in the treatment [...]

Eiger BioPharmaceuticals Announces Proposed Public Offering of Common Stock

October 22nd, 2018|

Eiger BioPharmaceuticals Announces Proposed Public Offering of Common Stock PALO ALTO, Calif., October 22, 2018 – Eiger BioPharmaceuticals, Inc. (NASDAQ: EIGR), focused on the development and commercialization of targeted therapies for rare diseases, today announced that it has commenced an underwritten public offering of its common stock.  Eiger intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock offered in the public offering on the same terms and conditions [...]